Novartis Bets Big on Cardiovascular Biotech With $3bn Anthos Deal
Swiss pharmaceutical giant Novartis has announced an agreement to acquire Anthos Therapeutics from Blackstone Life Sciences in a deal valued at up to $3.1 Billion. The deal includes a $925 Million upfront payment, with additional payouts tied to future regulatory and commercial success. Investment Implications For Novartis: This move allows Novartis to regain abelacimab, a […]
German 
English